

# Jaromir Hradec

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1243620/jaromir-hradec-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44 papers	14,168 citations	26 h-index	46 g-index
46 ext. papers	16,576 ext. citations	14.4 avg, IF	5.86 L-index

#	Paper	IF	Citations
44	European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 613-25	12.3	316
43	Comparison of therapy of heart failure patients in the Czech Republic and Europe. Data from the ESC Heart Failure Long-Term Registry. <i>Cor Et Vasa</i> , <b>2016</b> , 58, e609-e614	0.3	
42	Comparison of hospitalized and ambulatory patients with heart failure in the Czech Republic and Europe. Data from the ESC Heart Failure Long-Term Registry. <i>Cor Et Vasa</i> , <b>2015</b> , 57, e6-e11	0.3	2
41	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials. <i>Circulation</i> , <b>2015</b> , 131, 1486-94; discussion 1494	16.7	66
40	ExtraHF survey: the first European survey on implementation of exercise training in heart failure patients. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 631-8	12.3	54
39	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 2387-97	59.2	2371
38	Ivabradine in stable coronary artery disease without clinical heart failure. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1091-9	59.2	315
37	Summary of the ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Prepared by the Czech Society of Cardiology. <i>Cor Et Vasa</i> , <b>2013</b> , 55, e25-e40	0.3	1
36	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 947-59	12.3	63
35	Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 589-96	2.5	7
34	Natriuretic peptides in heart failure. <i>Cor Et Vasa</i> , <b>2013</b> , 55, e370-e376	0.3	4
33	Assessing cardiac patients for fitness to drive motor vehicles. Expert consensus statement of the Czech Society of Cardiology-2012 update. <i>Cor Et Vasa</i> , <b>2013</b> , 55, e217-e224	0.3	1
32	Treatment of anemia with darbepoetin alfa in systolic heart failure. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1210-9	59.2	331
31	Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1125-35	27.4	248
30	Comparison of clinical guidelines for the diagnosis and treatment of chronic heart failure of ESC and ESC 2012. <i>Cor Et Vasa</i> , <b>2013</b> , 55, e301-e308	0.3	
29	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Heart Journal</i> , <b>2013</b> , 34, 3117-27	9.5	47
28	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1173-84	12.3	388

27	Czech Society of Cardiology Guidelines for the Diagnosis and Treatment of Chronic Heart Failure 2011. <i>Cor Et Vasa</i> , <b>2012</b> , 54, e113-e134	0.3	9
26	Left ventricle remodeling in men with moderate to severe volume-dependent hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2012</b> , 13, 426-34	3	6
25	Eplerenone in patients with systolic heart failure and mild symptoms. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 11-21	59.2	1890
24	An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 66-74	12.3	15
23	Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study). <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 517-21	3	5
22	Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 795-801	12.3	88
21	The rationale and design of the PERindopril GENetic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. <i>Cardiovascular Drugs and Therapy</i> , <b>2009</b> , 23, 171-81	3.9	24
20	Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. <i>Circulation</i> , <b>2009</b> , 120, 2188-96	16.7	138
19	The characteristics and drug therapy of patients with chronic systolic heart failure of ischemic etiology in the Czech Republic. <i>Cor Et Vasa</i> , <b>2009</b> , 51, 268-273	0.3	2
18	Irbesartan in patients with heart failure and preserved ejection fraction. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 2456-67	59.2	1307
17	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2008</b> , 372, 807-16	40	775
16	Rosuvastatin in older patients with systolic heart failure. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 2248-61	59.2	1098
15	Recurrent peripheral arterial embolism from metastatic lung choriocarcinoma--a case report. <i>Angiology</i> , <b>2006</b> , 57, 127-9	2.1	1
14	Impact of essential hypertension and primary aldosteronism on plasma brain natriuretic peptide concentration. <i>Blood Pressure</i> , <b>2006</b> , 15, 302-7	1.7	10
13	Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. <i>Circulation</i> , <b>2004</b> , 110, 2618-26	16.7	282
12	Management of grown up congenital heart disease. <i>European Heart Journal</i> , <b>2003</b> , 24, 1035-84	9.5	345
11	American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 154-224	15.1	1187
10	Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. <i>American Heart Journal</i> , <b>2003</b> , 146, 110	4.9	17

9	Expert consensus document on management of cardiovascular diseases during pregnancy. <i>European Heart Journal</i> , <b>2003</b> , 24, 761-81	9.5	253
8	Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). <i>Lancet, The</i> , <b>2003</b> , 362, 782-8	40	1630
7	Nitroglycerin induced syncope occurs in subjects with delayed phase shift of baroreflex action. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>2002</b> , 25, 828-32	1.6	6
6	ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With	15.1	634
5	Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia and (fenofibrate versus atorvastatin trial--FAT). <i>Cardiovascular Research</i> , <b>2001</b> , 52, 290-8	9.9	112
4	Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). <i>American Journal of Cardiology</i> , <b>1999</b> , 83, 1506-9, A8	3	56
3	Valsartan and atenolol in patients with severe essential hypertension. <i>Journal of Human Hypertension</i> , <b>1998</b> , 12, 563-7	2.6	28
2	Long-term echocardiographic follow-up of acromegalic heart disease. <i>American Journal of Cardiology</i> , <b>1993</b> , 72, 205-10	3	35
1	Septal aneurysm with associated anomalies. <i>Pediatric Radiology</i> , <b>1985</b> , 15, 415-7	2.8	1